在此处获取。上次访问时间:2024年1月。 3European Medicines Agency. HyQvia 100 mg/mL solution for infusion for subcutaneous use Summary of Product Characteristics. 获取链接:https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf。 4Dalakas MC; Medscape. Adv...
与其他产品相比,HyQvia在用药频率及便利性方面具有极大的优势。HyQvia 100mg/mlShire Deutschland GmbHWirksame Bestandteile und InhaltsstoffeImmunglobulin(human) 100mg= Immunglobulin GmgGlycin HilfstoffImmunglobulin A 140µg HilfstoffWasser, für Injektionszwecke HilfstoffHyaluronidase, rekombinant(human)Al...
批准日期:2014年9月15日 公司:百特和Halozyme HYQVIA(免疫球蛋白输注10%[人]与重组人透明质酸酶[Immune Globulin Infusion 10% [Human]with RecombinantHuman Hyaluronidase])皮下给药的溶液警告:血栓形成 查看完整的盒装警告的完整处方信息 •免疫球蛋白产品可能会发生血栓形成,包括HYQVIA。危险因素可包括高龄,长...
HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. See Important Safety Information & Blood Clot Warning for Patients.
3European Medicines Agency. HyQvia 100 mg/mL solution for infusion for subcutaneous use Summary of Product Characteristics. 获取链接:https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf。 4Dalakas MC; Medscape. Advances in the diagnosis, pathogenesis and...
HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. See Important Safety Information & Blood Clot Warning for Patients.
1 欧洲药品管理局。HyQvia 100 mg/mL皮下输注溶液产品特性摘要(HyQvia 100 mg/mL solution for infusion for subcutaneous use Summary of Product Characteristics)。网址:https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf。
HYQVIA [Ig Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution. See Safety Info & Thrombosis Warning in Full Prescribing Info.
1歐洲藥品管理局。HyQvia 100 mg/mL皮下輸注溶液產品特性摘要(HyQvia 100 mg/mL solution for infusion for subcutaneous use Summary of Product Characteristics)。網址:https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf。
Background: We describe the design of a non-interventional, prospective, uncontrolled, multicenter, open-label, post-marketing surveillance study to be conducted in the US and other countries where recombinant human hyaluronidase (rHuPH20)-facilitated subcutaneous infusion of immunoglobulin G (fSCIG; ...